Academic Research Organization Becomes an OmniComm CRO Preferred ProgramTM Partner

FT. LAUDERDALE, FL–(EMWNews – August 5, 2008) – OmniComm Systems, Inc. (OTCBB: OMCM), a

leader in integrated electronic data capture (EDC) solutions for clinical

trials, today announced that Colorado Prevention Center (CPC) has chosen

OmniComm as their preferred provider as they move from paper data

collection to EDC for their clinical trials. CPC delivers all of the

traditional services of a CRO with additional emphasis on the quality of

the science and trial conduction. Joining the CRO Preferred Program allows

them to offer superior electronic data capture services and support to

their clinical development clients worldwide.

“We conducted an exhaustive search of EDC vendors that drilled down to 30

high level candidates. Ten (10) of those companies were issued a request

for proposal and only 4 leading companies were chosen to provide

demonstrations of their products and services. OmniComm exceeded our

expectations with the best services and software by far and was the clear

winner in the evaluation,” said Evan King, COO of Colorado Prevention

Center. “We are very excited to have made the move to EDC and we look

forward to working in tandem with the team at OmniComm.”

CPC (www.cpcmed.org) is dedicated to improving health through clinical

research and integrating scientific evidence into community prevention

programs. CPC supports every aspect of clinical research, including study

design, comprehensive trial management and completion of final study

reports. In addition to these traditional services, CPC provides a unique

quality intervention program that improves the ability to detect treatment

effect. CPC also provides unmatched scientific leadership and publications

of academic hypotheses arising from industry and non-industry research.

“When companies like CPC join our CRO Preferred Program, they gain an EDC

partner that shares their dedication to delivering excellence,” said

Stephen Johnson, COO of OmniComm. “In this highly competitive marketplace,

CROs need to know that they have a real partner that they can trust to

provide the same high caliber deliverables that their clients have come to

expect. Working with OmniComm ensures that level of security for our

partners that choose to use TrialMaster™ for EDC.”

About OmniComm

OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet

solutions to pharmaceutical, biotechnology, research and medical device

organizations that conduct life changing clinical trial research.

OmniComm’s growing base of satisfied customers is a direct result of the

company’s commitment to deliver products and services that ensure ease of

use, faster study build, ease of integration and better performance.

OmniComm’s client intuitive pricing model allows companies that range from

small to mid-size to large scale institutions to safely and efficiently

capitalize on their clinical research investments. OmniComm Systems, Inc.

has corporate headquarters in Ft. Lauderdale, Florida with offices in Bonn,

Germany, Tula, Russia, California, Maryland, New York, North Carolina and

Texas.

Safe Harbor Disclaimer

Statements about OmniComm’s future expectations, including without

limitation, future revenues and earnings, plans and objectives for the

future operations, future agreements, future economic performance,

operations and all other statements in this press release other than

historical facts are “forward-looking statements” within the meaning of

Section 27A of the Securities Act of 1933, Section 21E of the Securities

Exchange Act of 1934, and as that term is defined in the Private Securities

Litigation Reform Act of 1995. OmniComm intends that such forward-looking

statements be subject to the Safe Harbors created thereby. Since these

statements involve risks and uncertainties, including but not limited to

economic competitive, governmental, contractual and technological factors

affecting OmniComm’s operations, markets and profitability, actual results

could differ materially and adversely from the expected results.